Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742301 | 0.88 | NPC1 (0.60) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL28791140 | 0.84 | TP53 (0.66) | GAANPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL726223 | 0.83 | GAA (0.63) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3192014 | 0.81 | LMNA (0.77) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL8215174 | 0.81 | GAA (1.00) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1014753 | 0.79 | NPC1 (0.66) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL619878 | 0.79 | GAA (0.71) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5858228 | 0.79 | GAA (0.71) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL10986439 | 0.78 | LMNA (0.61) | GAANPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3282470 | 0.78 | CYP1A2 (0.61) | GAANPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805367-B | Triazole pyrimidine derivative and preparation method and application thereof | 郑州大学 | 2023-04-07 | — | — | CN | claimed |
| CN-114805367-A | Triazole pyrimidine derivative and preparation method and application thereof | 郑州大学 | 2022-07-29 | — | — | CN | claimed |
| CN-105693517-A | 3,4-dihydroxyl phenethyl alcohol fibrate carboxylic ester compound and preparation method and application thereof | 西安交通大学 | 2016-06-22 | — | — | CN | claimed |
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | claimed |
| US-9145410-B2 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-29 | — | — | US | claimed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | claimed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | claimed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | claimed |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2012-05-17 | — | — | US | claimed |
| EP-2427447-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | claimed |
| EP-0060094-B1 | GUANIDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-22 | — | — | EP | claimed |
| EP-0150099-A1 | Guanidine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-07-31 | — | — | EP | claimed |
| US-4496564-A | HISTAMINE H-2 ANTIGONISTS | ICI AMERICAS INC. (US) | 1985-01-29 | — | — | US | claimed |
| US-4447441-A | ANTIHISTAMINE, ANTIULCER AND ANTISECRETORY AGENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-05-08 | — | — | US | claimed |
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | claimed |
| EP-0060094-A2 | Guanidine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-09-15 | — | — | EP | claimed |
| EP-0060093-A2 | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-09-15 | — | — | EP | claimed |
| US-4342765-A | Guanidine derivatives and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-08-03 | — | — | US | claimed |
| US-4251628-A | HYDROLYSIS OF OLIGOPEPTIDES FOR RADIOISOTOPE ASSAY | VENTREX LABORATORIES, INC. | 1981-02-17 | — | — | US | claimed |
| EP-0014057-A1 | Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-08-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL4I1, IL2 | GAA 2478/4885NPC1 3331/4885RAB9A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.